Previous studies have suggested that SEG may exert various effects, such as alleviating inflammation, reducing lipid peroxidation, decreasing α‐synuclein accumulation, inhibiting apoptotic pathways, and increasing the expression of autophagy‐related proteins.[33, 34, 35, 36] Research has shown that GLP1R agonists can alleviate motor dysfunction in PD animal models.[27, 37, 38] Several clinical studies have confirmed that GLP1R agonists can improve motor function in PD patients.[39, 40, 41] The safety profile and multifunctionality of SEG make it a promising candidate for future PD treatment. This evidence concerns the gene GLP1R and Parkinson disease.